KR20190100880A - Composition for preventing, treating or improving obesity or obesity-related disease comprising extracts of Angelica tenuissima - Google Patents

Abstract

The present invention relates to a composition for preventing, treating, or alleviating obesity or obesity-related complications containing an extract of Angelica tenuissima as an active component. The extract of Angelica tenuissima according to the present invention is confirmed to have an effect of inhibiting the increase in body weight and fasting blood glucose by a high-fat diet in a dietary obesity-induced mouse model, and thus increasing an energy metabolic rate. In addition, the extract of Angelica tenuissima has an effect of alleviating insulin resistance and dyslipidemia, and an effect of alleviating fatty liver, hepatotoxicity, and inflammation. Therefore, the extract of Angelica tenuissima can be usefully used for preventing, treating or alleviating not only obesity, but also obesity-related complications that can be caused by weight gain.

Description

Composition for preventing, treating or improving obesity or obesity-related disease comprising extracts of Angelica tenuissima}

The present invention relates to a composition for the prevention, treatment, or improvement of obesity or obesity-related complications comprising the extract as an active ingredient.

Obesity generally means that the body has an excessive amount of fat tissue, and the energy consumed by food is not balanced with the energy consumed by physical activity, so that surplus energy is accumulated as body fat. Obesity is a very diverse cause, including genetic factors, environmental factors caused by irregular eating habits, lack of exercise or excessive food intake, psychological factors caused by depression, boredom and excessive stress, and pathological factors caused by thyroid or corticosteroid changes. It is caused by the recent economic growth and lifestyle changes, many changes in eating habits, busy modern people are increasing in weight and obesity due to high calorie diet and fast exercise such as fast food.

 Obesity is perceived more seriously because of the many complications that can be caused by obesity than its own risk, and if body fat is abnormally increased due to energy imbalance over time, diabetes, hyperlipidemia, heart disease, stroke, arteriosclerosis And various metabolic diseases such as fatty liver and adult disease. In addition, since obesity can cause mental illnesses such as social isolation, alienation, lack of confidence, and depression, obesity is a serious social problem worldwide, and the need for prevention and treatment of obesity is very important. have.

Obesity can be treated with diet, regular exercise, lifestyle improvements such as behavioral therapy, and medications such as appetite suppressants and fat absorption inhibitors. Obesity is a chronic disease that requires long-term use when attempting medication. Currently, products approved for long-term use in Korea for more than three months include sibutramine, an appetite suppressant, and orlistat, an lipase inhibitor. There is). However, most of these anti-obesity drugs are psychotropic drugs that act on the central nervous system to control appetite, so they have side effects such as headache and vomiting and there are problems such as abuse. Therefore, there is a need for research to develop a material having high stability and excellent anti-obesity effect that can solve the side effects of the commercially available anti-obesity agents.

On the other hand, Angelica tenuissima is a perennial herb of the dicotyledon plant Asteraceae, which grows in deep valleys throughout the country. The height of the bone is 30 ~ 80cm, hairless and fragrant throughout the grass. Stems stand straight, branched, leaves displaced, leaves on roots have long petioles, leaves on stems have leaf crests. 3 times divided into pinnate leaf and split pieces are streaks. Flowers bloom in August-September with inflorescences of double flowers. There are about 10 large peduncles and 20-22 small peduncles.

The taste of Gobon is spicy and warm, and the spicy taste is strong, and it is used for headache, fever, sea water, sputum, and runny nose caused by external appearance, and it is strong, windproof, and gastric in combination with limb paralysis joint pain caused by wind and humidity. Use it. It also has the effect of stopping the pain of head pain. In addition, the original contains volatile essential oils, essential oils have a calming, analgesic, antipyretic, anti-inflammatory action. In addition, it inhibits the intestinal and uterine smooth muscle and has a strong inhibitory effect on ringworm, and it is one of the medicinal plants having the effect of neurodermatitis, itching, and skin rash. The root of Gobon is used as a herbal medicine. The root contains 1.5% essential oil, and its main components include 3-butyl phthalide and cndilide.

Therefore, while the original has been used in the development of cosmetic compositions and the like, the use as a composition for the prevention, treatment, or improvement of obesity or obesity-related complications is not well known.

Thus, the present inventors have confirmed that the extracts directly inhibit the increase in weight, so that it can be used as a composition for the prevention, treatment, or improvement of obesity, the prevention, treatment, Or it can be used for improvement purposes.

Korean Patent No. 1480696

The present inventors have tried to develop a composition for preventing, treating, or improving obesity or obesity-related complications having high stability and directly inhibiting weight gain, which can solve the problems of conventional anti-obesity agents. The present invention was completed based on this by confirming the excellent anti-obesity effect of the extract.

Accordingly, an object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of obesity or obesity-related complications comprising the extract extract as an active ingredient.

In addition, an object of the present invention is to provide a food composition for the prevention or improvement of obesity or obesity-related complications containing a high extract as an active ingredient.

However, the technical problem to be achieved by the present invention is not limited to the above-mentioned problem, another task that is not mentioned will be clearly understood by those skilled in the art from the following description.

In order to achieve the above object, the present invention is a pharmaceutical composition for the prevention or treatment of obesity or obesity-related complications, including the extract as an active ingredient,

Obesity-related complications include type 2 diabetes; Insulin resistance syndrome; Impaired glucose tolerance; Visceral fat syndrome; Dyslipidemia; Hepatotoxic diseases including drug liver damage, viral liver damage, hepatitis, cirrhosis, liver cancer or hepatic coma; High blood pressure; stroke; Atherosclerosis; Heart failure; angina pectoris; Myocardial infarction; Fatty liver; Gallbladder disease; Sleep apnea; ventilation; Herniated disc; Osteoarthritis; Dysmenorrhea; Colon cancer; Breast cancer; And it is one or more selected from the group consisting of ovarian cancer, it provides a pharmaceutical composition.

In addition, the present invention is a food composition for the prevention or improvement of obesity or obesity-related complications, containing the extract as an active ingredient,

Obesity-related complications include type 2 diabetes; Insulin resistance syndrome; Impaired glucose tolerance; Visceral fat syndrome; Dyslipidemia; Hepatotoxic diseases including drug liver damage, viral liver damage, hepatitis, cirrhosis, liver cancer or hepatic coma; High blood pressure; stroke; Atherosclerosis; Heart failure; angina pectoris; Myocardial infarction; Fatty liver; Gallbladder disease; Sleep apnea; ventilation; Herniated disc; Osteoarthritis; Dysmenorrhea; Colon cancer; Breast cancer; And it is one or more selected from the group consisting of ovarian cancer, it provides a food composition.

In another embodiment of the present invention, the composition may inhibit the increase in weight.

In another embodiment of the present invention, the composition may increase the energy metabolic rate.

In another embodiment of the present invention, the composition may inhibit the increase in blood glucose.

In another embodiment of the present invention, the composition may inhibit the increase of plasma insulin concentration or HOMA-IR which is an indicator of insulin resistance.

In another embodiment of the present invention, the composition may inhibit the increase in plasma lipid concentration.

In another embodiment of the present invention, the composition may inhibit the increase in liver tissue cholesterol concentration.

In another embodiment of the present invention, the composition may inhibit the increase of plasma hepatotoxicity indicator.

In another embodiment of the present invention, the composition may increase plasma adiponectin content and inhibit plasma resistin content.

As another embodiment of the present invention, the extract extract after adding the extraction solvent to the extract; And lyophilizing and then extracting the extracted extract under reduced pressure. It can be prepared through.

As another embodiment of the present invention, the extraction solvent is water, C ₁ to C ₄ lower alcohol, n-hexane, ethyl acetate, acetone, butyl acetate, 1,3-butylene glycol, methylene chloride, and these It may be one selected from the group consisting of a mixed solvent of.

As another embodiment of the present invention, the food composition may be a dietary supplement composition.

The present invention also provides a method of preventing or treating obesity or obesity-related complications, comprising administering the composition to a subject.

The present invention also provides a use of the composition for the prevention or treatment of obesity or obesity-related complications.

Gobon extract according to the present invention was confirmed that the dietary obesity-induced mouse model suppresses the increase of body weight and fasting glucose by high fat diet, and has an effect of increasing the energy metabolic rate. In addition, insulin resistance and dyslipidemia as well as the effect of improving fatty liver, hepatotoxicity and inflammation have been found to be effective. Therefore, Kobon extract can be usefully used for anti-obesity functional food and drug development, etc. In addition, Kobon extract of the present invention is also used for the prevention, treatment, or improvement of obesity-related complications that can be caused by weight gain. It is expected to be possible.

1 is a diagram briefly showing an experimental design using a dietary obesity-induced mouse model in order to evaluate the anti-obesity effect of the extract extract according to an embodiment of the present invention.
Figure 2 is the normal diet group (ND), high fat diet group (HFD) according to an embodiment of the present invention by measuring the weight of the mice at a weekly interval for 4 weeks, after confirming that the obesity is well induced, high-fat diet group at 4 (HFD) is divided into a high-fat diet group (HFD) and a high extract extract (AT) to measure the weight of the mice for 13 weeks to compare the weight loss and weight gain suppression effect according to the breeding period.
Figure 3 is a liver (kidney), and the normal diet group (ND), high-fat diet group (HFD) and high-bon extract extract group (AT) mice for 17 weeks after breeding according to an embodiment of the present invention; Figure showing the weight per 100 g body weight after the muscles (muscle) extracted and weighed.
Figure 4 measures the energy consumption for 24 hours of the normal diet group (ND), high-fat diet group (HFD), and high-bon extract extract group (AT) mice using the animal metabolic rate measuring device according to an embodiment of the present invention Energy metabolic rate is divided into day and night and shown in quantitative comparison.
FIG. 5 shows the fasting blood glucose levels of the normal diet group (ND) and the high-fat diet group (HFD) mice according to one embodiment of the present invention for 4 weeks, and then observes the fasting glucose level according to the high-fat diet. The dietary group (HFD) was divided into the high-fat diet group (HFD) and the extract extract (MA), and the fasting blood glucose levels of the mice were measured at 4 week intervals for 12 weeks. Drawing.
6 is a view showing the plasma insulin concentration and HOMA-IR measurement results of the normal diet group (ND), high fat diet group (HFD), and high-bon extract extract group (AT) mice according to an embodiment of the present invention.
Figure 7 measured the plasma cholesterol of the normal diet group (ND), high-fat diet group (HFD) mice according to an embodiment of the present invention for 4 weeks after observing the increase in cholesterol according to the high-fat diet, high-fat diet at 4 weeks Divided group (HFD) into high-fat diet group (HFD) and high-fat extract group (AT) to measure plasma cholesterol of mice at 4 week intervals for 13 weeks and compare the changes in plasma cholesterol increase inhibition according to the breeding period to be.
8 is a view showing a comparison of the plasma lipid concentration analysis results of the normal diet group (ND), high fat diet group (HFD), and high-bon extract extract group (AT) mice according to an embodiment of the present invention.
9 is a diagram showing the changes in liver tissue cholesterol of the normal diet group (ND), high fat diet group (HFD), and high-bon extract extract group (AT) mice according to an embodiment of the present invention.
Figure 10 is a diagram showing a comparison of blood liver toxicity indicators of the normal diet group (ND), high fat diet group (HFD), and high-bon extract extract group (AT) mice according to an embodiment of the present invention.
11 is a view showing a comparison of the blood adiponectin and resistin content of the normal diet group (ND), high fat diet group (HFD), and high-bon extract extract group (AT) mice according to an embodiment of the present invention.

The present invention is a pharmaceutical composition for the prevention or treatment of obesity or obesity-related complications, including the extract as an active ingredient,

Obesity-related complications include type 2 diabetes; Insulin resistance syndrome; Impaired glucose tolerance; Visceral fat syndrome; Dyslipidemia; Hepatotoxic diseases including drug liver damage, viral liver damage, hepatitis, cirrhosis, liver cancer or hepatic coma; High blood pressure; stroke; Atherosclerosis; Heart failure; angina pectoris; Myocardial infarction; Fatty liver; Gallbladder disease; Sleep apnea; ventilation; Herniated disc; Osteoarthritis; Dysmenorrhea; Colon cancer; Breast cancer; And it is one or more selected from the group consisting of ovarian cancer, it provides a pharmaceutical composition.

The obesity, which is a disease to be prevented or treated according to the present invention, refers to a state in which fat cells proliferate and differentiate due to metabolic disorders, and thus fat is excessively accumulated, and hypertension, diabetes mellitus, and dyslipidemia Associated complications, including metabolic syndrome, may be caused. When energy absorption increases relative to consumption, the mass and volume of fat cells increase, resulting in an increase in the mass of fat tissue.

According to a specific experimental example of the present invention, the obesity-related complications are type 2 diabetes; Insulin resistance syndrome; Dyslipidemia; Hepatotoxic diseases including drug liver damage, viral liver damage, hepatitis, cirrhosis, liver cancer or hepatic coma; Or fatty liver, but is not limited thereto.

As used herein, the term "prevention" means any action that inhibits or delays the development of obesity or obesity-related complications by administration of a pharmaceutical composition according to the invention.

As used herein, the term "treatment" refers to any action in which symptoms for obesity or obesity-related complications improve or benefit altered by administration of a pharmaceutical composition according to the invention.

The present invention also provides a method for preventing or treating obesity or obesity-related complications comprising administering the pharmaceutical composition to a subject.

As used herein, the term "administration" means providing a subject with any of the compositions of the present invention in any suitable manner.

As used herein, the term "individual" refers to a subject in need of treatment of a disease, and more specifically, human or non-human primates, mice, dogs, cats, horses, cattle, and the like. Mean mammal.

In addition, the present invention provides a use of the pharmaceutical composition for the prevention or treatment of obesity or obesity-related complications.

In the present invention, the "extract" is the extract itself, such as an extract obtained by the extraction process of the original, a diluent or concentrate of the extract, a dried product obtained by drying the extract, a modifier or purified product of the extract, or a mixture thereof. And extracts of all formulations that can be formed using extracts.

In the solid extract of the present invention, the method of extracting the solid is not particularly limited and may be extracted according to a method commonly used in the art. Non-limiting examples of the extraction method, hot water extraction method, ultrasonic extraction method, filtration method, reflux extraction method and the like, these may be carried out alone or in combination of two or more methods.

The type of extraction solvent used for extracting the above-mentioned main body in the present invention is not particularly limited, and according to conventional methods known in the art for extracting the extract from natural products, that is, under the conditions of ordinary temperature and pressure It can be extracted using a phosphorus solvent. For example, in the present invention, the high extract is composed of water, a lower alcohol having 1 to 4 carbon atoms, n-hexane, ethyl acetate, acetone, butyl acetate, 1,3-butylene glycol, methylene chloride, and a mixed solvent thereof. It can be extracted using one or more solvents selected from.

The prepared extract can then be filtered or concentrated or dried to remove the solvent, it can be carried out both filtration, concentration and drying. For example, the filtration may use a filter paper or a vacuum filter, the concentration may be a vacuum concentrator, the drying may be a freeze-drying method, but is not limited thereto.

In one experimental example of the present invention, in order to evaluate the anti-obesity effect of the extract extracted by the above method, the experiment was conducted using a dietary obesity-induced mouse model.

In one experimental example of the present invention, male C57BL / 6J mice were classified into a normal diet group (ND) and a high fat diet group (HFD), and the weight was measured while breeding for 4 weeks, and the high fat diet group (HFD) was a normal diet group (ND). Obesity was induced by a sharp increase in body weight compared to). After 4 weeks, the high-fat diet group (HFD) was again classified into the high-fat diet group (HFD) and the solid extract pay group (AT), and reared for 13 weeks to measure the weight. In the case of high fat diet not only reduced the weight gain compared to the control group, but also directly observed that the weight increase by observing that the main extract has a direct effect on weight loss (see Experimental Example 1-1 and Figure 2) .

In addition, mice in each group were bred for 17 weeks in the same manner, and sacrificed, and livers, kidneys, and muscles were extracted and weighed. As a result, in the high-fat diet group (HFD), liver weights increased and kidney and muscle weights. On the other hand, the hepatic weight was decreased and the kidney and muscle weights were increased in the high-fat extract group compared to the high-fat diet group (see Experimental Examples 1-2 and FIG. 3).

In another experimental example of the present invention, the energy metabolic rate of day and night was measured quantitatively by measuring energy consumption during 24 hours, respectively, and in the case of high-fat diet group (HFD), both day and night energy metabolic rate were significantly lower. On the other hand, it was confirmed that the energy extract group (AT) significantly increased the energy metabolic rate compared to the high-fat diet group (HFD) during the day time (see Experimental Example 2 and Figure 4).

In another experimental example of the present invention, the fasting glucose level of the normal diet group (ND), high-fat diet group (HFD) mice was measured for 4 weeks, and the fasting glucose level was observed according to the high-fat diet. (HFD) was divided into high-fat diet group (HFD) and high-fat extract group (AT) to measure fasting blood glucose levels of mice at 4 week intervals for 12 weeks, and compared with the change in inhibition of fasting blood glucose increase according to the breeding period. In the case of the paying group (AT), compared to the high-fat diet group (HFD) it was confirmed that suppressing the fasting blood glucose increase (see Experimental Example 3 and Figure 5).

In another experimental example of the present invention, the plasma insulin concentration in the blood collected from the abdominal venous vein at the expense of the respective mouse groups and the insulin resistance indicators as a result of the analysis of insulin concentration and HOMA in the high-bon extract extract group (AT) It was confirmed that the IR value was decreased (see Experimental Example 4 and FIG. 6).

In another experimental example of the present invention, the plasma diet of the normal diet group (ND), high-fat diet group (HFD) mice was measured for 4 weeks, after monitoring the increase in cholesterol according to the high-fat diet, high-fat diet group (HFD) at 4 weeks ) Were divided into high-fat diet (HFD) and high-fat extract (AT) groups, and the cholesterol content of the mice was measured every four weeks for 13 weeks. Compared with the plasma total cholesterol was confirmed to inhibit (see Experimental Example 5 and Figure 7).

In another experimental example of the present invention, plasma lipid concentration analysis was performed by collecting blood by the same method at the time of sacrifice of mice in each group, and in the case of the high-fat extract group (AT), compared to the high-fat diet group (HFD), the plasma neutral lipid was , Cholesterol, phospholipids and nonHDL-cholesterol concentration was confirmed to inhibit the increase (see Experimental Example 6 and Figure 8).

In another experimental example of the present invention, the liver tissues of the mice in each group were extracted and analyzed by comparing the liver tissue cholesterol concentrations, the total extract of the high-fat extract group (AT) compared to the high-fat diet group (HFD) increased the total liver tissue cholesterol It was confirmed to suppress (see Experimental Example 7 and FIG. 9).

In addition, GOT (glutamic oxaloacetic transaminase) and GPT (glutamic pyruvic transaminase), which are indicators of hepatotoxicity, in blood collected by the same method of mice in each group, were analyzed in the high-fat diet group (AT) compared to the high-fat diet group (HFD) Remarkably low blood GOT and GPT were confirmed (see Experimental Example 8 and FIG. 10).

In another experimental example of the present invention, the plasma adiponectin and resistin content in blood collected by the same method, the blood adiponectin content of the high-bon extract extract group (AT) significantly increased compared to the high-fat diet group (HFD) , It was confirmed that the blood resistin content was reduced (see Experimental Example 9 and FIG. 11).

Therefore, the experimental results of the present invention showed that the extract extract has the effect of inhibiting the increase in weight and fasting blood glucose, and increases the energy metabolic rate. In addition, the extract of the present invention was found to have an effect of improving insulin resistance and dyslipidemia, as well as improving fatty liver, hepatotoxicity and inflammation.

On the other hand, the "pharmaceutical composition" in the present invention means that is prepared for the purpose of preventing or treating a disease, each can be used in formulated in various forms according to conventional methods. For example, it may be formulated in oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, and syrups, and may be formulated in the form of external preparations, suppositories, and sterile injectable solutions.

In addition, the pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier in addition to the active ingredient. At this time, the pharmaceutically acceptable carrier is commonly used in the preparation, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose , Polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil, and the like. In addition to the above components, it may further include a lubricant, wetting agent, sweetener, flavoring agent, emulsifier, suspending agent, preservative and the like.

The pharmaceutical compositions of the present invention can be administered orally or parenterally (eg, applied intravenously, subcutaneously, intraperitoneally or topically) according to the desired method, and the dosage is determined by the condition and weight of the patient, Depending on the extent, drug form, route of administration, and time, it may be appropriately selected by those skilled in the art.

The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. As used herein, the term “pharmaceutically effective amount” means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level refers to the type of disease, the severity, the activity of the drug, It may be determined according to the sensitivity to the drug, the time of administration, the route of administration and the rate of release, the duration of treatment, factors including the drug used concurrently and other factors well known in the medical field. The pharmaceutical compositions according to the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered as single or multiple doses. Taking all of the above factors into consideration, it is important to administer an amount that can achieve the maximum effect with a minimum amount without side effects, which can be readily determined by one skilled in the art.

The present invention also provides a method for preventing or treating obesity or obesity-related complications comprising administering the pharmaceutical composition to a subject.

As used herein, the term "individual" means a subject in need of a method for the prevention or treatment of a disease, and more specifically, for humans or non-human primates, mice, rats, Mean mammals such as dogs, cats, horses and cows.

In addition, the present invention is a food composition for the prevention or improvement of obesity or obesity-related complications containing a high extract,

Obesity-related complications include type 2 diabetes; Insulin resistance syndrome; Impaired glucose tolerance; Visceral fat syndrome; Dyslipidemia; Hepatotoxic diseases including drug liver damage, viral liver damage, hepatitis, cirrhosis, liver cancer or hepatic coma; High blood pressure; stroke; Atherosclerosis; Heart failure; angina pectoris; Myocardial infarction; Fatty liver; Gallbladder disease; Sleep apnea; ventilation; Herniated disc; Osteoarthritis; Dysmenorrhea; Colon cancer; Breast cancer; And it is one or more selected from the group consisting of ovarian cancer, it provides a food composition.

In the present invention, the food composition may be a health functional food composition, but is not limited thereto.

As used herein, the term "improvement" refers to any action that at least reduces the parameters associated with the condition being treated, for example the extent of symptoms. At this time, the health functional food composition may be used simultaneously or separately with the agent for treatment before or after the onset of the disease in order to prevent or improve obesity or obesity-related complications.

In the present invention, the "health food composition" is characterized in that it is formulated as one selected from the group consisting of tablets, pills, powders, granules, powders, capsules and liquid formulations, including one or more of carriers, diluents, excipients and additives. It is done.

Foods that can be added to the extract of the present invention include various foods, powders, granules, tablets, capsules, syrups, beverages, gums, teas, vitamin complexes, and health functional foods. As additives which may be further included in the present invention, natural carbohydrates, flavoring agents, nutrients, vitamins, minerals (electrolytes), flavoring agents (synthetic flavoring agents, natural flavoring agents, etc.), colorants, fillers, pactic acid and salts thereof, Alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, antioxidants, glycerin, alcohols, carbonation agents, and one or more components selected from the group consisting of pulp can be used. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As the flavoring agent, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used.

In addition to the above, the composition according to the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and neutralizing agents, fact acids and salts thereof, alginic acid and salts thereof, organic acids, protection Sex colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages and the like.

In addition, other compositions of the present invention may contain pulp for the production of natural fruit juices and vegetable beverages. These components can be used independently or in combination.

Specific examples of the carrier, excipient, diluent and additives include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, erythritol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium phosphate, calcium silicate, Group consisting of microcrystalline cellulose, polyvinylchirrolidone, cellulose, polyvinylpyrrolidone, methylcellulose, water, sugar syrup, methyl hydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate, and mineral oil It is preferred that at least one selected from be used.

Hereinafter, preferred examples and experimental examples are presented to help understand the present invention. However, the following Examples and Experimental Examples are provided only to more easily understand the present invention, and the contents of the present invention are not limited by the following Examples and Experimental Examples.

Example 1. Preparation of Gobon Extracts

After distilled water was added to the original, the extract was pressurized at 105 ° C. for 5 hours, and the extraction frequency was twice. The extract was concentrated under reduced pressure and freeze-dried to prepare the extract. The yield of the extract was calculated to be 51.68%.

Example  2. Statistical Analysis

Statistical analysis was performed by t-test, and all experimental results were considered to show statistically significant difference when p <0.05.

(HFD vs. ND: * p <0.05, ** p <0.01, *** p <0.001; HFD vs. AT: #p <0.05, ## p <0.01, ### p <0.001)

Experimental Example  One. In the original extract  Weight change and organ weight change analysis

1-1. Weight change analysis

In order to determine the effect of the intake of the extract extract prepared in Example 1 in the dietary obesity-induced mouse model, the experiment was designed and carried out as shown in the schematic diagram shown in FIG. Specifically, four-week-old male C57BL / 6J mice (n = 32) were purchased from Jackson, USA, and adapted to Lab chow for one week, and were fed a normal diet group (ND, n = 10) and a high fat diet group (HFD, n =). It was observed that obesity was well induced by breeding for 4 weeks and weighing at weekly intervals. After the 4th week of breeding, the high-fat diet group (HFD, n = 22) was replaced with the high-fat diet group (n = 12) and the solid extract extract group (AT, 1% of the original extract + high fat diet, n = 10), respectively. The animals were classified for 13 weeks and weighed at weekly intervals.

As a result, as shown in Figure 2, in the case of the high-fat diet group (HFD) compared to the normal diet group (ND), the body weight increased sharply, whereas in the case of the pay extract group (AT) salary from week 2 to high-fat diet Significant weight loss was observed.

Therefore, it can be seen from the results that the extract extracts directly inhibit the weight gain.

1-2. Long-term weight analysis

In addition to the weight change analysis of Experimental Example 1-1, the purpose of the present invention was to determine the effect of the intake of the extract extract prepared in Example 1 on the dietary obesity-induced mouse model. To this end, mice of each group bred for 17 weeks by the method of Experimental Example 1-1 were fasted for 12 hours, anesthetized through inhalation with isoflurane (isoflurane) (Baxter, USA), sacrificed and organs were removed. Liver, kidney, and muscle tissues of each mouse were rinsed several times with phosphate buffered saline (PBS), drained, weighed, and expressed as weight per 100 g of body weight.

As a result, as shown in Figure 3, the high-fat diet group (HFD) liver tissue weight was significantly increased compared to the normal diet group (ND), the liver extract extract group (AT) liver weight was significantly higher than the high-fat diet group Decreased. In addition, the height and muscle weight per unit weight was significantly decreased in the high-fat diet group compared to the normal diet group, but the height and muscle weight of the high-fat extract group was significantly increased compared to the high-fat diet group. Through the above results, it was confirmed that the extract extracts the liver weight, the weight of the kidney and muscle increases.

Experimental Example 2. Analysis of the effect of the extract extract on the energy metabolic rate

The purpose of the present invention was to determine whether the intake of the extract prepared in Example 1 affects energy expenditure (EE) as well as weight and blood sugar lowering effects. To this end, the energy consumption of the mouse was measured using the animal metabolic rate measuring device (Oxylet; Panlab, Cornella, Spain) by the method of Experimental Example 1-1. More specifically, after calibrating the measuring device with oxygen and carbon, the flow rate in the cage was adjusted to 3 L / min. Thereafter, each mouse was placed in a separate metabolic cage, and the energy consumption for 24 hours was measured. Subsequently, the energy consumption was derived by substituting Equation 1 below.

[Equation 1]

EE (kcal / day / body weight ^0.75 ) = Vo ₂ × 1.44 × [3.815+ (1.232 × Vo ₂ / Vco ₂ )]

As a result, as shown in FIG. 4, the energy metabolic rate of day and night was quantitatively compared, respectively, and the high-fat diet group (HFD) showed significantly lower energy metabolism rate than the normal diet group (ND), whereas the extract of the main bone In the pay group, the energy metabolism rate was significantly higher during the day than in the high-fat diet group. Therefore, through the above results, it was found that the extract extract increases the energy metabolic rate.

Experimental Example 3. Analysis of the effect of the extract extract on blood glucose

It was confirmed through the results of Experimental Examples 1-1 and 1-2 that the intake of the extract extracted in Example 1 has an effect of reducing the weight and liver weight, and in addition to this it was to determine whether it affects the blood sugar change . To this end, the mice were fasted for 12 hours during the four-week breeding period by the method of Experimental Example 1-1, and blood glucose levels were measured by fasting blood glucose by measuring blood fastening by tailing. Fasting group was divided into high-fat diet group (HFD) and solid extract extract group (AT), and fasting blood glucose was measured in the same manner as above during the 12-week breeding period.

As a result, as shown in FIG. 5, the high-fat diet group (HFD) maintained a significantly increased blood sugar level compared to the normal diet group (ND), while the main extract pay group (AT) for 12 weeks It was confirmed that the high-fat diet maintained lower blood sugar levels than the group fed throughout the breeding period. Through the above results, it was found that the extract extract has an excellent hypoglycemic effect.

Experimental Example 4. Analysis of the effect of the extract on the blood diabetes related markers

As a result of Experiment 3, it was confirmed that the intake of the herbal extract prepared in Example 1 had a hypoglycemic effect. In addition, it affected the plasma insulin concentration, a diabetes-related hormone, and HOMA-IR, an insulin resistance index. To find out. To this end, the mice of each group were fasted for 12 hours at the end of breeding by the method of Experimental Example 1-2, sacrificed, and blood was collected from the inferior vena cava. The collected blood was treated with heparin, centrifuged at 1,000 × g and 4 ° C. for 15 minutes, and then plasma was collected and stored at 70 ° C. until sample analysis. At this time, the blood insulin concentration was measured using the collected plasma using a MILLIPLEX detection kit (Merck Millipore, USA). After that, the homeostasis model assessment of insulin resistance (HOMA-IR), which is an index of insulin sensitivity, was calculated by substituting Equation 2 below.

[Equation 2]

HOMA-IR = [fasting glucose (mmol / L) × fasting insulin (μLU / mL)] 22.5

As a result, as shown in Figure 6, the high-fat diet group (HFD) significantly increased the plasma insulin content and HOMA-IR levels compared to the normal diet group (ND), whereas the high-fat diet (AT) high-fat diet group (AT) It was confirmed that the plasma insulin content and HOMA-IR levels were significantly reduced compared to the two groups (HFD). Therefore, through the above results, it can be seen that the extract extract is effective in improving insulin resistance.

Experimental Example 5. Analysis of the effect of the extract on plasma total cholesterol concentration

After fasting the mice for 12 hours during the four-week breeding period by the method of Experimental Example 1-1 and observing the elevated cholesterol by the high-fat diet in the collected blood, the high-fat diet group again at the 4th week of breeding Plasma total cholesterol was measured in the same manner as described above during the 13-week breeding period. In this case, quantification of plasma total cholesterol was measured using a test solution (Asan kit, Korea) applying the enzyme method.

As a result, as shown in Figure 7, in the high-fat diet group (HFD) compared to the normal diet group (ND), the plasma total cholesterol content increased throughout the breeding period, while in the case of the high-fat extract group (AT) breeding From the 12th week, it was confirmed that the plasma cholesterol level was lower than that of the high-fat diet group.

Experimental Example 6. Analysis of the effect of the extract extract on plasma lipid concentration

In addition to the results of Experimental Example 5, we tried to find out whether the intake of the extract extract prepared in Example 1 also affects the plasma lipid concentration. To this end, plasma triglycerides, total cholesterol, phospholipids (PL) and nonHDL-cholesterol contents were compared in the plasma collected by the method of Experimental Example 4. At this time, the plasma triglyceride and cholesterol content was measured using a test solution (Asan kit, Korea), and the phospholipid was measured using a Wako enzymatic kit (Wako Chemicals, USA). Quantification of plasma nonHDL-cholesterol calculated the difference between total plasma cholesterol and HDL-cholesterol.

As a result, as shown in Figure 8, the high-fat diet group (HFD) compared to the normal diet group (ND) plasma triglyceride (cholesterol), total cholesterol (cholesterol), phospholipids and nonHDL-cholesterol content all increased, while The extract fed group (AT) was significantly decreased in all plasma lipid concentrations compared to the high fat diet group (HFD). Therefore, it was confirmed that the extract extract has an effect on improving dyslipidemia.

Experimental Example 7. Analysis of the effect of the extract extract on liver tissue cholesterol concentration

It was confirmed through the results of Experimental Example 1-2 that the intake of the extract extract has the effect of reducing the weight of liver tissue, and in addition to this it was to determine whether it affects the liver tissue lipid concentration. To this end, after breeding for 17 weeks by the method of Experimental Example 1-1, the extracted liver tissue was finely chopped and extracted with lipids with chloroform: methanol (1: 1) solvent, volatilized with nitrogen gas at 37 ° C and diluted with isopropanol. Then, 3 mM cholic acid (sodium salt) and 0.5% Triton X-100 were mixed as an emulsifier in the enzyme solution for lipid quantification. The total cholesterol content of liver was measured using Asan enzymatic kits (Asan, Seoul).

As a result, as shown in Figure 9, the high-fat diet group (HFD) significantly increased liver tissue cholesterol content compared to the normal diet group (ND), while the high-fat diet group (AT) high-fat diet group (HFD) It was confirmed to reduce the liver tissue cholesterol content compared to). Therefore, it was found that the extract extract has an effect on improving fatty liver.

Experimental Example 8. Analysis of the effect of the extract extract on hepatotoxicity marker

The results of Experimental Examples 1-2 and 7 confirmed that the intake of the extract extracts had an effect of reducing the liver tissue weight and lipid concentration, in addition to GOT (glutamic oxaloacetic transaminase) and GPT ( We analyzed the glutamic pyruvic transaminase activity. To this end, plasma GOT and GPT from blood collected by the method of Experimental Example 4 were measured using a test solution (Asan kit, Korea).

As a result, as shown in Figure 10, the high-fat diet group (HFD) showed significantly increased plasma GOT and GPT content compared to the normal diet group (ND), while the high-fat extract group (AT) high-fat diet It was confirmed that the plasma GOT and GPT contents were significantly reduced compared to the two groups (HFD). Therefore, it was confirmed that the extract extract has an effect of inhibiting hepatotoxicity.

Experimental Example 9. Analysis of the effect of the extract on the plasma adipokine content

In order to determine the effect of the medicinal extract according to the present invention on the plasma adipoline (adipoline) content, the anti-inflammatory markers of plasma adiponectin (adiponecitn) and the inflammation marker from the blood collected by the method of Experimental Example 4 (resistin) ), The plasma adiponectin content was measured using the Mouse adiponectin / Acrp30 ELISA kit (R & D systems, USA), and the plasma resistin content was measured using the MILLIPLEX detection kit (Merck Millipore, USA). .

As a result, as shown in Figure 11, the high-fat diet group (HFD) significantly reduced the plasma adiponectin content compared to the normal diet group (ND), while the high-fat extract group (AT) high-fat diet Plasma adiponectin content was increased as compared to the two groups (HFD). In addition, the high-fat diet group (HFD) has an increased plasma resistin content as compared to the normal diet group (ND), whereas the high-fat diet group (AT) has a significant decrease in the content of plasma resistin compared to the high-fat diet group (HFD) It was confirmed. Therefore, through the above results, it was confirmed that the extract extract has anti-inflammatory efficacy.

The foregoing description of the present invention is intended for illustration, and it will be understood by those skilled in the art that the present invention may be easily modified in other specific forms without changing the technical spirit or essential features of the present invention. will be. Therefore, it should be understood that the embodiments and the experimental examples described above are illustrative in all respects and are not restrictive.

Claims (20)

As a pharmaceutical composition for the prevention or treatment of obesity or obesity-related complications, containing the extract as an active ingredient,
Obesity-related complications include type 2 diabetes; Insulin resistance syndrome; Impaired glucose tolerance; Visceral fat syndrome; Dyslipidemia; Hepatotoxic diseases including drug liver damage, viral liver damage, hepatitis, cirrhosis, liver cancer or hepatic coma; High blood pressure; stroke; Atherosclerosis; Heart failure; angina pectoris; Myocardial infarction; Fatty liver; Gallbladder disease; Sleep apnea; ventilation; Herniated disc; Osteoarthritis; Dysmenorrhea; Colon cancer; Breast cancer; And one or more selected from the group consisting of ovarian cancer, pharmaceutical composition.
The method of claim 1,
The composition, characterized in that to inhibit the increase in weight, pharmaceutical composition.
The method of claim 1,
The composition is characterized in that to increase the energy metabolic rate, pharmaceutical composition.
The method of claim 1,
The composition is characterized in that to suppress the increase in blood sugar, pharmaceutical composition.
The method of claim 1,
The composition is characterized in that to suppress the increase in plasma insulin concentration or insulin resistance HOMA-IR, pharmaceutical composition.
The method of claim 1,
The composition, characterized in that to inhibit the increase in plasma lipid concentration, pharmaceutical composition.
The method of claim 1,
The composition is characterized in that to inhibit the increase in liver cholesterol concentration, pharmaceutical composition.
The method of claim 1,
The composition is characterized in that to inhibit the increase in plasma hepatotoxicity indicator, pharmaceutical composition.
The method of claim 1,
The composition is characterized in that to increase the plasma adiponectin (adiponectin) content, inhibiting the plasma resistin (resistin) content, pharmaceutical composition.
The method of claim 1,
Extracting the extract after adding the extraction solvent to the extract; And lyophilizing and then extracting the extracted extract under reduced pressure.
Characterized in that prepared through, pharmaceutical composition.
The method of claim 10,
The extraction solvent is _one selected from the group consisting of water, C ₁ to C ₄ lower alcohols, n-hexane, ethyl acetate, acetone, butyl acetate, 1,3-butylene glycol, methylene chloride, and mixed solvents thereof. Characterized in that the pharmaceutical composition.
As a food composition for preventing or improving obesity or obesity-related complications, containing the extract as an active ingredient,
Obesity-related complications include type 2 diabetes; Insulin resistance syndrome; Impaired glucose tolerance; Visceral fat syndrome; Dyslipidemia; Hepatotoxic diseases including drug liver damage, viral liver damage, hepatitis, cirrhosis, liver cancer or hepatic coma; High blood pressure; stroke; Atherosclerosis; Heart failure; angina pectoris; Myocardial infarction; Fatty liver; Gallbladder disease; Sleep apnea; ventilation; Herniated disc; Osteoarthritis; Dysmenorrhea; Colon cancer; Breast cancer; And one or more selected from the group consisting of ovarian cancer, food composition.
The method of claim 12,
The composition is characterized in that to suppress the increase in weight, food composition.
The method of claim 12,
The composition is characterized in that to increase the energy metabolic rate, food composition.
The method of claim 12,
The composition is characterized in that to suppress the increase in blood sugar, food composition.
The method of claim 12,
The composition is a food composition, characterized in that the composition inhibits the increase in plasma insulin concentration or HOMA-IR which is an indicator of insulin resistance.
The method of claim 12,
The composition is characterized in that to inhibit the increase in plasma lipid concentration, food composition.
The method of claim 12,
The composition is characterized in that to suppress the increase in liver cholesterol concentration, food composition.
The method of claim 12,
The composition, characterized in that to inhibit the increase in plasma hepatotoxicity indicator, food composition.
The method of claim 12,
The food composition is a health functional food composition, characterized in that the food composition.

Images